JP2022530524A5 - - Google Patents
Info
- Publication number
- JP2022530524A5 JP2022530524A5 JP2021564298A JP2021564298A JP2022530524A5 JP 2022530524 A5 JP2022530524 A5 JP 2022530524A5 JP 2021564298 A JP2021564298 A JP 2021564298A JP 2021564298 A JP2021564298 A JP 2021564298A JP 2022530524 A5 JP2022530524 A5 JP 2022530524A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- cancer
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193434A JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックFR-α抗体及びイムノコンジュゲート |
| JP2026059845A JP2026116994A (ja) | 2019-04-29 | 2026-03-31 | バイパラトピックFR-α抗体及びイムノコンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840297P | 2019-04-29 | 2019-04-29 | |
| US62/840,297 | 2019-04-29 | ||
| US201962879864P | 2019-07-29 | 2019-07-29 | |
| US62/879,864 | 2019-07-29 | ||
| PCT/US2020/030245 WO2020223221A1 (en) | 2019-04-29 | 2020-04-28 | Biparatopic fr-alpha antibodies and immunoconjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193434A Division JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックFR-α抗体及びイムノコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530524A JP2022530524A (ja) | 2022-06-29 |
| JP2022530524A5 true JP2022530524A5 (cg-RX-API-DMAC7.html) | 2023-05-10 |
| JP7585230B2 JP7585230B2 (ja) | 2024-11-18 |
Family
ID=73028723
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564298A Active JP7585230B2 (ja) | 2019-04-29 | 2020-04-28 | バイパラトピックFR-α抗体及びイムノコンジュゲート |
| JP2024193434A Active JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックFR-α抗体及びイムノコンジュゲート |
| JP2026059845A Pending JP2026116994A (ja) | 2019-04-29 | 2026-03-31 | バイパラトピックFR-α抗体及びイムノコンジュゲート |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193434A Active JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックFR-α抗体及びイムノコンジュゲート |
| JP2026059845A Pending JP2026116994A (ja) | 2019-04-29 | 2026-03-31 | バイパラトピックFR-α抗体及びイムノコンジュゲート |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11396543B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3962935A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7585230B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220004687A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114222756A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020265568B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3138272A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL287451A (cg-RX-API-DMAC7.html) |
| MA (1) | MA55818A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202111109UA (cg-RX-API-DMAC7.html) |
| TW (2) | TWI872065B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020223221A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2997044A4 (en) * | 2013-05-14 | 2017-03-22 | ImmunoGen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| NZ717140A (en) | 2013-08-30 | 2022-05-27 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
| SG11202111109UA (en) | 2019-04-29 | 2021-11-29 | Immunogen Inc | Biparatopic fr-alpha antibodies and immunoconjugates |
| US11912781B2 (en) * | 2021-01-13 | 2024-02-27 | Visterra, Inc. | Humanized complement 5A receptor 1 antibodies and methods of use thereof |
| WO2022217022A1 (en) * | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| KR20240017024A (ko) * | 2021-06-04 | 2024-02-06 | 이뮤노젠 아이엔씨 | 가용성 fr-알파를 이용한 환자의 암 치료 |
| KR20240159839A (ko) | 2022-03-09 | 2024-11-06 | 아스트라제네카 아베 | FRα에 대한 결합 분자 |
| TW202409080A (zh) * | 2022-07-26 | 2024-03-01 | 美商沙塔克實驗室股份有限公司 | 用於治療卵巢癌之組合療法 |
| TW202448517A (zh) | 2023-02-16 | 2024-12-16 | 瑞典商阿斯特捷利康公司 | 用治療性結合分子治療癌症的組合療法 |
| US12649790B2 (en) | 2023-07-03 | 2026-06-09 | Medicovestor, Inc. | Proteins that bind SP17 including fully-human anti-SP17 antibodies |
| US12624097B2 (en) | 2023-07-03 | 2026-05-12 | Medicovestor, Inc. | Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
| US12673991B2 (en) | 2023-12-26 | 2026-07-07 | Medicovestor, Inc. | Methods of crosslinking IgG |
| US12121587B1 (en) | 2023-12-26 | 2024-10-22 | Medicovestor, Inc. | Dimeric antibodies |
| US12600795B2 (en) | 2023-12-26 | 2026-04-14 | Medicovestor, Inc. | Oligomeric IgG for immunotherapeutics and diagnostics |
| CN122535429A (zh) | 2024-01-05 | 2026-08-07 | 信达生物制药(苏州)有限公司 | 抗体以及包含其与tlr7/8激动剂的免疫偶联物及其用途 |
| TW202608930A (zh) * | 2024-06-05 | 2026-03-01 | 大陸商長春金賽藥業有限責任公司 | 靶向葉酸受體α(FRα)的抗體、雙特異性抗體和偶聯物,及其製備和用途 |
| US20260001950A1 (en) * | 2024-07-01 | 2026-01-01 | Medicovestor, Inc. | Methods of enhancing efficacy of immunoconjugates using paired human antibodies targeted at non-overlapping b-cell epitopes on the same antigen |
| US20260078179A1 (en) * | 2024-07-18 | 2026-03-19 | Novarock Biotherapeutics, Ltd. | Cdh17 antibodies and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| CN105777907B (zh) | 2010-02-24 | 2020-03-17 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| SG189957A1 (en) * | 2010-11-05 | 2013-06-28 | Morphotek Inc | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| ES2661466T3 (es) | 2011-04-01 | 2018-04-02 | Immunogen, Inc. | Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1 |
| US20120282282A1 (en) | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
| SG11201500938XA (en) | 2012-08-31 | 2015-04-29 | Immunogen Inc | Diagnostic assays and kits for detection of folate receptor 1 |
| EP2997044A4 (en) | 2013-05-14 | 2017-03-22 | ImmunoGen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| NZ717140A (en) | 2013-08-30 | 2022-05-27 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
| JP6463744B2 (ja) | 2013-10-08 | 2019-02-06 | イミュノジェン, インコーポレイテッド | 抗folr1免疫抱合体投薬レジメン |
| US20170247449A1 (en) | 2014-06-06 | 2017-08-31 | Kyowa Hakko Kirin Co., Ltd | Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism |
| MA40539A (fr) | 2014-09-02 | 2016-03-10 | Immunogen Inc | Procédés de formulation de compositions de conjugués anticorps-médicaments |
| CN122075735A (zh) | 2015-09-17 | 2026-05-26 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| IL298414B2 (en) | 2017-02-28 | 2024-12-01 | Immunogen Inc | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |
| GB201707864D0 (en) | 2017-05-16 | 2017-06-28 | Inst Of Cancer Research: Royal Cancer Hospital | Platinum-reistant cancer treatment |
| JP7604226B2 (ja) | 2017-09-05 | 2024-12-23 | イミュノジェン, インコーポレイテッド | 患者の試料中のヒト葉酸受容体1を検出するための方法 |
| TWI826393B (zh) | 2017-09-22 | 2023-12-21 | 美商免疫遺傳股份有限公司 | 使用陽離子交換層析法分離三輕鏈抗體 |
| AU2019206587A1 (en) | 2018-01-12 | 2020-08-06 | Immunogen, Inc. | Methods for antibody drug conjugation, purification, and formulation |
| SG11202111109UA (en) * | 2019-04-29 | 2021-11-29 | Immunogen Inc | Biparatopic fr-alpha antibodies and immunoconjugates |
| KR20240017024A (ko) * | 2021-06-04 | 2024-02-06 | 이뮤노젠 아이엔씨 | 가용성 fr-알파를 이용한 환자의 암 치료 |
-
2020
- 2020-04-28 SG SG11202111109UA patent/SG11202111109UA/en unknown
- 2020-04-28 AU AU2020265568A patent/AU2020265568B2/en active Active
- 2020-04-28 WO PCT/US2020/030245 patent/WO2020223221A1/en not_active Ceased
- 2020-04-28 KR KR1020217037919A patent/KR20220004687A/ko active Pending
- 2020-04-28 TW TW109114175A patent/TWI872065B/zh active
- 2020-04-28 CA CA3138272A patent/CA3138272A1/en active Pending
- 2020-04-28 TW TW113151397A patent/TW202515623A/zh unknown
- 2020-04-28 CN CN202080037442.7A patent/CN114222756A/zh active Pending
- 2020-04-28 JP JP2021564298A patent/JP7585230B2/ja active Active
- 2020-04-28 US US16/860,822 patent/US11396543B2/en active Active
- 2020-04-28 EP EP20798751.2A patent/EP3962935A4/en active Pending
- 2020-04-28 MA MA055818A patent/MA55818A/fr unknown
-
2021
- 2021-10-20 IL IL287451A patent/IL287451A/en unknown
-
2022
- 2022-06-10 US US17/838,016 patent/US11834498B2/en active Active
-
2023
- 2023-10-24 US US18/493,623 patent/US20240182560A1/en not_active Abandoned
-
2024
- 2024-11-05 JP JP2024193434A patent/JP7844591B2/ja active Active
-
2025
- 2025-08-12 US US19/297,369 patent/US20260061058A1/en active Pending
-
2026
- 2026-03-31 JP JP2026059845A patent/JP2026116994A/ja active Pending
- 2026-07-01 AU AU2026205205A patent/AU2026205205A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230138930A1 (en) | Tissue factor-targeted antibody-drug conjugate | |
| US20240173427A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| TWI872065B (zh) | 雙互補位FR-α抗體及免疫結合物 | |
| US20230173093A1 (en) | Charge variant linkers | |
| CN105451775B (zh) | 药物抗体缀合物 | |
| RU2765098C2 (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| US10618935B2 (en) | Antibody-drug conjugate (ADC) and method for forming the same | |
| CN110240654A (zh) | 结合cd73的抗体-药物偶联物 | |
| JP2018524373A5 (cg-RX-API-DMAC7.html) | ||
| US12006370B2 (en) | Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy | |
| CN102065891A (zh) | 新型协同效应 | |
| JP2023504187A5 (cg-RX-API-DMAC7.html) | ||
| JP2021528471A5 (cg-RX-API-DMAC7.html) | ||
| CN107614488A (zh) | 新型亲水连接体和其在配体‑药物共轭偶联物上的应用 | |
| US20210260212A1 (en) | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy | |
| CN120835792A (zh) | 抗体-药物偶联物靶向治疗前列腺癌和其他肿瘤 | |
| WO2023098691A1 (zh) | 抗体药物偶联物及其用途 | |
| CN115052663A (zh) | Alk5抑制剂缀合物及其用途 | |
| IL273384B2 (en) | Methods of preventing methionine oxidation in immunoconjugates | |
| CN119156231A (zh) | 提高鹅膏蕈毒素-抗体缀合物的治疗指数的方法 | |
| JP2024532677A5 (cg-RX-API-DMAC7.html) | ||
| RU2021130453A (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты | |
| RU2023100251A (ru) | Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство | |
| RU2021104563A (ru) | Конъюгаты антитело-лекарственное средство и их применение |